Search results for "informatics"

showing 10 items of 2542 documents

Editorial: Pathophysiologic Insights From Biomarker Studies in Neurological Disorders

2020

business.industryneurodegenerationneuroimmunologyBioinformaticslcsh:RC346-429PathophysiologyEditorialNeuroimmunologyNeurologybiomarkerBiomarker (medicine)MedicineNeurology (clinical)pathomechanismbusinesslcsh:Neurology. Diseases of the nervous systempathophysiologyFrontiers in Neurology
researchProduct

Editorial: Physiology and Pathophysiology of Heat Shock Protein 60

2020

business.industrypost translational modificationshepatocellular carcinomaacquired chaperonopathieBioinformaticsHsp60Biochemistry Genetics and Molecular Biology (miscellaneous)BiochemistryPathophysiologypost translational modificationlcsh:Biology (General)cardiovascular diseasegenetic chaperonopathieHeat shock proteinPosttranslational modificationMedicineHSP60acquired chaperonopathiesbusinessgenetic chaperonopathieslcsh:QH301-705.5Molecular Biologychaperonotherapy
researchProduct

MiR-221 promotes stemness of breast cancer cells by targeting DNMT3b

2016

// Giuseppina Roscigno 1, 2 , Cristina Quintavalle 1, 2 , Elvira Donnarumma 3 , Ilaria Puoti 1 , Angel Diaz-Lagares 4 , Margherita Iaboni 1 , Danilo Fiore 1 , Valentina Russo 1 , Matilde Todaro 5 , Giulia Romano 6 , Renato Thomas 7 , Giuseppina Cortino 7 , Miriam Gaggianesi 5 , Manel Esteller 4 , Carlo M. Croce 6 , Gerolama Condorelli 1, 2 1 Department of Molecular Medicine and Medical Biotechnology, “Federico II” University of Naples, Naples, Italy 2 IEOS-CNR, Naples, Italy 3 IRCCS-SDN, Naples, Italy 4 Epigenetic and Cancer Biology Program (PEBC) IDIBELL, Hospital Duran I Reynals, Barcelona, Spain 5 Department of Surgical and Oncological Sciences, Cellular and Molecular Pathophysiology Lab…

cancer stem cells0301 basic medicineMicro RNAsCellular differentiationADNDNMTStem cellsStem cell markermedicine.disease_causeBioinformaticsMCF-7 Cell0302 clinical medicineBreast cancerHEK293 CellTumor Cells CulturedDNA (Cytosine-5-)-MethyltransferasesOligonucleotide Array Sequence AnalysisMicroscopy ConfocalReverse Transcriptase Polymerase Chain ReactionMicroRNAHomeodomain ProteinNanog Homeobox ProteinmicroRNAsGene Expression Regulation NeoplasticOncology030220 oncology & carcinogenesisMCF-7 CellsNeoplastic Stem CellsRNA InterferenceCèl·lules mareBreast NeoplasmResearch PaperHumanHomeobox protein NANOGBlotting WesternBreast NeoplasmsBiologyCàncer de mama03 medical and health sciencesmicroRNAs breast cancer cancer stem cells DNMTBreast cancerCancer stem cellCell Line TumorSpheroids CellularmedicineHumansHomeodomain ProteinsOligonucleotide Array Sequence AnalysiCancer stem cellGene Expression ProfilingCancerDNAmedicine.diseaseMolecular medicineMicroRNAsHEK293 Cells030104 developmental biologyDNA (Cytosine-5-)-MethyltransferaseCancer researchNeoplastic Stem CellCarcinogenesisOctamer Transcription Factor-3
researchProduct

Intratumoral Heterogeneity, Its Contribution to Therapy Resistance and Methodological Caveats to Assessment

2014

Cancer is one of the most urgent health issues of today. According to WHO, the number of cancer cases is expected to increase by 75% in the next two decades (1). Despite some remarkable achievements in the fields of cancer prevention and early detection, the goal of developing effective anti-cancer therapies still remains unmet. Tumor recurrence due to treatment resistance is the most common cause of death from cancer. Delineating cellular and molecular mechanisms underlying tumor recurrence is of prime importance for the ability to improve the efficacy of existing therapies and develop new strategies to cancer treatment.

cancer stem cellsCancer Researchmedicine.medical_specialtytumor clones selectionEarly detectionintratumor heterogeneityBioinformaticslcsh:RC254-282Intratumor heterogeneityCancer stem cellmedicinecancerTreatment resistanceIntensive care medicineCancer preventionbusiness.industryintratumor spatiotemporal patternsCancerOpinion Articlelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasetumor recurrenceCancer treatmentTumor recurrenceOncologybusinessanti-cancer therapyFrontiers in Oncology
researchProduct

TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells

2015

Metastatic growth in breast cancer (BC) has been proposed as an exclusive property of cancer stem cells (CSCs). However, formal proof of their identity as cells of origin of recurrences at distant sites and the molecular events that may contribute to tumor cell dissemination and metastasis development are yet to be elucidated. In this study, we analyzed a set of patient-derived breast cancer stem cell (BCSC) lines. We found that in vitro BCSCs exhibit a higher chemoresistance and migratory potential when compared with differentiated, nontumorigenic, breast cancer cells (dBCCs). By developing an in vivo metastatic model simulating the disease of patients with early BC, we observed that BCSCs…

cancer stem cellsTAZAnimals; Biomarkers Tumor; Breast Neoplasms; Cell Line Tumor; Disease-Free Survival; Female; Gene Expression Regulation Neoplastic; Humans; Mice; Neoplasm Metastasis; Neoplasm Recurrence Local; Neoplastic Stem Cells; Transcription Factors; Xenograft Model Antitumor AssaysCancer ResearchBioinformaticschemotherapyMetastasistaz; breast cancerMiceNeoplasm Metastasiseducation.field_of_studyTumorIntracellular Signaling Peptides and ProteinsCell cycleGene Expression Regulation NeoplasticLocalNeoplastic Stem Cellsbreast cancer; cancer stem cells; chemotherapy; metastasis; TAZ; Animals; Biomarkers Tumor; Breast Neoplasms; Cell Line Tumor; Disease-Free Survival; Female; Gene Expression Regulation Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Mice; Neoplasm Metastasis; Neoplasm Recurrence Local; Neoplastic Stem Cells; Xenograft Model Antitumor Assays; Molecular Biology; Genetics; Cancer ResearchFemaleStem cellPopulationBreast NeoplasmsBiologyDisease-Free SurvivalCell Linebreast cancer cancer stem cells TAZBreast cancerbreast cancerCancer stem cellSettore MED/04 - PATOLOGIA GENERALECell Line TumormedicineBiomarkers TumorGeneticsmetastasisAnimalsHumanseducationMolecular BiologyHippo signaling pathwayNeoplasticCancermedicine.diseaseXenograft Model Antitumor AssaysNeoplasm RecurrenceGene Expression RegulationTranscriptional Coactivator with PDZ-Binding Motif ProteinsCancer researchTrans-ActivatorsNeoplasm Recurrence LocalBiomarkersTranscription Factors
researchProduct

Role of biomarkers in monitoring antiblastic cardiotoxicity

2016

Early detection of anticancer drug-induced cardiotoxicity (CTX) has been evaluated by most international scientific cardiology and oncology societies. High expectations have been placed on the use of specific biomarkers. In recent years, conventional biomarkers and molecules of more recent interest have been tested and compared in the context of anticancer drug-related CTX. Encouraging results were obtained from studies on molecules of myocardial damage, such as troponin and markers of myocardial wall stress, including circulating natriuretic peptides, as well as from the assessment of the products of inflammation or circulating levels of free radicals. However, clear guidelines on their se…

cardiac toxicitymedicine.medical_specialtyantiblasticantineoplasticEarly detectionContext (language use)Antineoplastic Agentsantiblastic; anticancer drugs; antineoplastic; biomarkers; brain natriuretic peptide; cardiac toxicity; troponin; Cardiology and Cardiovascular Medicine030204 cardiovascular system & hematologyBioinformaticsbrain natriuretic peptideSensitivity and Specificity03 medical and health sciencesWall stress0302 clinical medicineCardiac toxicityNeoplasmsNatriuretic Peptide BrainmedicineHumansanticancer drugIntensive care medicineantineoplastic antiblastic anticancer drugs biomarkers brain natriuretic peptide cardiac toxicity troponinMonitoring PhysiologicCardiotoxicitybusiness.industrytroponinbiomarkersGeneral MedicineTime optimalCardiotoxicityanticancer drugsEarly DiagnosisCardiovascular Diseases030220 oncology & carcinogenesisbiomarkerbusinessCardiology and Cardiovascular Medicine
researchProduct

Cardiorespiratory Fitness Estimation Based on Heart Rate and Body Acceleration in Adults With Cardiovascular Risk Factors : Validation Study

2022

Publisher Copyright: © Antti-Pekka E Rissanen, Mirva Rottensteiner, Urho M Kujala, Jari L O Kurkela, Jan Wikgren, Jari A Laukkanen. Originally published in JMIR Cardio (https://cardio.jmir.org), 25.10.2022. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cardio, is properly cited. The complete bibliographic information, a link to the original publication on https://cardio.jmir.org, as well as this copyright and license information must be included. Background: C…

cardiorespiratory fitnesshypertensiondiabetesheart rate variabilityHealth Informaticsriskitekijätwearable technology3121 General medicine internal medicine and other clinical medicineterveysvaikutuksetsydän- ja verisuonitauditkohonnut verenpainetype 2 diabetespuettava teknologiaCardiology and Cardiovascular Medicineaikuistyypin diabetesmetabolinen oireyhtymäcardiopulmonary exercise test
researchProduct

Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients.

2007

Increasing evidence suggests that the quality-rather than just the quantity-of low-density lipoproteins (LDLs) exerts a great influence on cardiovascular risk. LDLs comprise multiple subclasses with discrete size and density, and different physicochemical composition, metabolic behaviors, and atherogenicity. Individuals generally cluster into 2 broad subgroups. Most have a predominance of large LDLs, and some have a higher proportion of small particles. Small, dense LDLs are good predictors of cardiovascular events and progression of coronary artery disease. Their predominance has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Tre…

cardiovascular riskRiskStatinmedicine.drug_classHypercholesterolemiasubclassePharmacologyBioinformaticschemistry.chemical_compoundClofibric AcidEzetimibemedicineHumansPharmacology (medical)Cholesterol absorption inhibitorRosuvastatinRisk factorRosuvastatin CalciumNational Cholesterol Education ProgramSulfonamidessmall dense LDLfibrateCholesterolbusiness.industryAnticholesteremic AgentsstatinGeneral MedicineCholesterol LDLEzetimibeFluorobenzenesRosuvastatin CalciumPyrimidineschemistrydiabeteCardiovascular DiseasesAzetidineslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessrosuvastatinmedicine.drugAdvances in therapy
researchProduct

Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options

2021

Dyslipidemia is a potent risk factor for the genesis and progression of cardiovascular disease (CVD), and both the concentration and type of low-density lipoproteins (LDL) augment this association. The small, dense LDL (sdLDL) subfraction is the subtype which is most strongly predictive of atherosclerosis and cardiovascular events. In addition to the traditionally available lipid-lowering treatment options, certain novel therapies have been shown to favorably impact sdLDL, among them the antidiabetic class of agents known as glucagon-like peptide 1 receptor agonists (GLP1-RAs). These drugs seem to alter the pathophysiologic mechanisms responsible for the formation and accumulation of athero…

cardiovascular riskSmall dense ldlQH301-705.5Medicine (miscellaneous)DiseaseBioinformaticsGeneral Biochemistry Genetics and Molecular BiologyTherapeutic approachpreventionDiabetes mellitusmedicineClinical significanceRisk factorBiology (General)therapydiabetesbusiness.industryBrief Reportdense LDLsmallmedicine.diseaseAtherogenic lipoproteinCardiovascular risk Dense LDL Diabetes GLP1 Prevention Small TherapyGLP1businessDyslipidemiaBiomedicines
researchProduct

Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes

2020

Type 2 Diabetes Mellitus (T2DM) is associated with a high risk of atherosclerotic cardiovascular (CV) disease. Among the well-known pathophysiologic factors, crucial roles are played by endothelial dysfunction (caused by oxidative stress and inflammation hyperglycemia-linked), increased activity of nuclear factor kB, altered macrophage polarization, and reduced synthesis of resident endothelial progenitor cells. As consequence, a potentially rapid progression of the atherosclerotic disease with a higher propensity to unstable plaque is arguable, finally leading to significantly increased cardiovascular mortality. Main managements are focused on both prevention and early diagnosis, by target…

cardiovascular riskcardiovascular risk; dipeptidyl peptidase-4 inhibitors; glucagon like peptide-1 receptor agonists; sodium glucose cotransporter-2 inhibitors; type 2 diabetes mellitustype 2 diabetes mellitusglucagon like peptide-1 receptor agonistslcsh:Medicine030209 endocrinology & metabolismInflammationType 2 diabetesDiseaseReview030204 cardiovascular system & hematologyHypoglycemiaBioinformaticsmedicine.disease_cause03 medical and health sciences0302 clinical medicinemedicineEndothelial dysfunctionAdverse effectbusiness.industrylcsh:RType 2 Diabetes MellitusGeneral Medicinemedicine.diseasesodium glucose cotransporter-2 inhibitorsmedicine.symptombusinessdipeptidyl peptidase-4 inhibitorsOxidative stressJournal of Clinical Medicine
researchProduct